CN1698649A - 以水滑石为载体的口服补锌剂及其制备与使用方法 - Google Patents
以水滑石为载体的口服补锌剂及其制备与使用方法 Download PDFInfo
- Publication number
- CN1698649A CN1698649A CN 200510050356 CN200510050356A CN1698649A CN 1698649 A CN1698649 A CN 1698649A CN 200510050356 CN200510050356 CN 200510050356 CN 200510050356 A CN200510050356 A CN 200510050356A CN 1698649 A CN1698649 A CN 1698649A
- Authority
- CN
- China
- Prior art keywords
- hydrotalcite
- zinc
- solution
- magnesium
- aluminum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 title claims abstract description 47
- 239000011701 zinc Substances 0.000 title claims abstract description 47
- 229910052725 zinc Inorganic materials 0.000 title claims abstract description 47
- 229960001545 hydrotalcite Drugs 0.000 title claims abstract description 44
- 229910001701 hydrotalcite Inorganic materials 0.000 title claims abstract description 44
- 238000000034 method Methods 0.000 title claims abstract description 24
- GDVKFRBCXAPAQJ-UHFFFAOYSA-A dialuminum;hexamagnesium;carbonate;hexadecahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-]C([O-])=O GDVKFRBCXAPAQJ-UHFFFAOYSA-A 0.000 title claims abstract 14
- 238000002360 preparation method Methods 0.000 title abstract description 12
- 239000012744 reinforcing agent Substances 0.000 title abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 42
- 238000003756 stirring Methods 0.000 claims abstract description 21
- 238000010438 heat treatment Methods 0.000 claims abstract description 14
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 claims abstract description 11
- 238000002156 mixing Methods 0.000 claims abstract description 11
- UJOHNXQDVUADCG-UHFFFAOYSA-L aluminum;magnesium;carbonate Chemical compound [Mg+2].[Al+3].[O-]C([O-])=O UJOHNXQDVUADCG-UHFFFAOYSA-L 0.000 claims abstract description 10
- 239000000843 powder Substances 0.000 claims abstract description 9
- 238000003825 pressing Methods 0.000 claims abstract description 9
- 239000002253 acid Substances 0.000 claims abstract description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 63
- 239000000243 solution Substances 0.000 claims description 40
- 229940091251 zinc supplement Drugs 0.000 claims description 27
- HVTHJRMZXBWFNE-UHFFFAOYSA-J sodium zincate Chemical compound [OH-].[OH-].[OH-].[OH-].[Na+].[Na+].[Zn+2] HVTHJRMZXBWFNE-UHFFFAOYSA-J 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 21
- 239000003795 chemical substances by application Substances 0.000 claims description 19
- 239000000725 suspension Substances 0.000 claims description 18
- 239000011777 magnesium Substances 0.000 claims description 17
- 238000001035 drying Methods 0.000 claims description 16
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims description 14
- -1 zincate anions Chemical class 0.000 claims description 13
- 238000000227 grinding Methods 0.000 claims description 12
- 159000000003 magnesium salts Chemical class 0.000 claims description 11
- 239000002002 slurry Substances 0.000 claims description 10
- 238000005406 washing Methods 0.000 claims description 10
- 241000282414 Homo sapiens Species 0.000 claims description 9
- 239000000047 product Substances 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 229910052749 magnesium Inorganic materials 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 6
- 239000011259 mixed solution Substances 0.000 claims description 6
- 150000004679 hydroxides Chemical class 0.000 claims description 5
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical group [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 4
- 229910052782 aluminium Inorganic materials 0.000 claims description 4
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical group Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 claims description 4
- YIXJRHPUWRPCBB-UHFFFAOYSA-N magnesium nitrate Chemical compound [Mg+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O YIXJRHPUWRPCBB-UHFFFAOYSA-N 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical class [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 3
- 235000012054 meals Nutrition 0.000 claims description 3
- BNGXYYYYKUGPPF-UHFFFAOYSA-M (3-methylphenyl)methyl-triphenylphosphanium;chloride Chemical compound [Cl-].CC1=CC=CC(C[P+](C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 BNGXYYYYKUGPPF-UHFFFAOYSA-M 0.000 claims description 2
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 claims description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 2
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 2
- 150000005837 radical ions Chemical class 0.000 claims description 2
- 230000003203 everyday effect Effects 0.000 claims 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 abstract description 5
- 238000006243 chemical reaction Methods 0.000 abstract description 4
- 159000000013 aluminium salts Chemical class 0.000 abstract description 3
- 229910000329 aluminium sulfate Inorganic materials 0.000 abstract description 2
- 150000001450 anions Chemical class 0.000 abstract description 2
- 238000002425 crystallisation Methods 0.000 abstract description 2
- 230000008025 crystallization Effects 0.000 abstract description 2
- 229910044991 metal oxide Inorganic materials 0.000 abstract description 2
- 150000004706 metal oxides Chemical class 0.000 abstract description 2
- 239000013078 crystal Substances 0.000 abstract 1
- 238000009837 dry grinding Methods 0.000 abstract 1
- 239000007943 implant Substances 0.000 abstract 1
- 230000002687 intercalation Effects 0.000 abstract 1
- 238000009830 intercalation Methods 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 238000001694 spray drying Methods 0.000 abstract 1
- 239000003826 tablet Substances 0.000 abstract 1
- PWZFXELTLAQOKC-UHFFFAOYSA-A dialuminum;hexamagnesium;carbonate;hexadecahydroxide;tetrahydrate Chemical compound O.O.O.O.[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-]C([O-])=O PWZFXELTLAQOKC-UHFFFAOYSA-A 0.000 description 30
- 235000011121 sodium hydroxide Nutrition 0.000 description 18
- 230000000694 effects Effects 0.000 description 12
- 206010048259 Zinc deficiency Diseases 0.000 description 11
- 238000009835 boiling Methods 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 239000002994 raw material Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 238000000975 co-precipitation Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 210000004211 gastric acid Anatomy 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000011573 trace mineral Substances 0.000 description 3
- 235000013619 trace mineral Nutrition 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229910052599 brucite Inorganic materials 0.000 description 2
- 239000013522 chelant Substances 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000001156 gastric mucosa Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 150000003751 zinc Chemical class 0.000 description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102000003846 Carbonic anhydrases Human genes 0.000 description 1
- 108090000209 Carbonic anhydrases Proteins 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 108020005199 Dehydrogenases Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000007501 Thymosin Human genes 0.000 description 1
- 108010046075 Thymosin Proteins 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000014461 bone development Effects 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000022159 cartilage development Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000004300 dark adaptation Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910000000 metal hydroxide Inorganic materials 0.000 description 1
- 150000004692 metal hydroxides Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000021062 nutrient metabolism Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 102000029752 retinol binding Human genes 0.000 description 1
- 108091000053 retinol binding Proteins 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000004246 zinc acetate Substances 0.000 description 1
- 229940062776 zinc aspartate Drugs 0.000 description 1
- 239000011746 zinc citrate Substances 0.000 description 1
- 235000006076 zinc citrate Nutrition 0.000 description 1
- 229940068475 zinc citrate Drugs 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
- 229940071566 zinc glycinate Drugs 0.000 description 1
- 229940120347 zinc preparations Drugs 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- POEVDIARYKIEGF-CEOVSRFSSA-L zinc;(2s)-2-aminobutanedioate;hydron Chemical compound [Zn+2].[O-]C(=O)[C@@H](N)CC(O)=O.[O-]C(=O)[C@@H](N)CC(O)=O POEVDIARYKIEGF-CEOVSRFSSA-L 0.000 description 1
- UOXSXMSTSYWNMH-UHFFFAOYSA-L zinc;2-aminoacetate Chemical compound [Zn+2].NCC([O-])=O.NCC([O-])=O UOXSXMSTSYWNMH-UHFFFAOYSA-L 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种以水滑石为载体的口服补锌剂及其制备与使用方法,这种口服补锌剂是一种含活性锌的水滑石。按重量百分比计,锌在水滑石中的含量为含量为9~11%。其制备方法是,将铝盐、镁盐和锌酸盐溶液在强烈搅拌的同时快速混和,并在水热条件下恒温晶化;也可以将铝碳酸镁加热到450~550℃得到双金属氧化物,利用阴离子插层反应,将锌酸根植入其晶格中,最后经干燥研磨或喷雾干燥制成固态粉末,并压制成片剂。基于本发明所制得的口服补锌剂,能通过缓释作用为人或动物提供必需的微量元素锌,减轻了直接服用无机锌盐、锌酸盐带来的各种副作用,增加了锌的吸收率。所补充的锌元素能够预防和治疗因锌缺乏引起的各种疾病。
Description
技术领域
本发明涉及一种以水滑石为载体的口服补锌剂及其制备与使用方法。
背景技术
锌是一种人体必需的微量元素,也是细胞内最丰富的微量元素。成人需10~15mg/d,儿童约需10mg/d。锌分布在人体各个组织器官内,视网膜、脉络膜、前列腺等器官含量最多,胰腺、肝、肾、肌肉也含有较多的锌。据中国医学科学院对18个省市学龄前儿童头发中含锌量测定,大约60%儿童含锌量低于正常值。人体中锌主要从食物中来,我国人群的膳食构成基本以谷物类为主,而谷物类的锌含量普遍较低。因此,锌摄入量不足是较普遍的现象,在儿童中尤为突出。
锌参与体内许多酶的合成。人体内有近200种酶的活性与锌有关,如DNA聚合酶,RNA合成酶,与营养物质代谢有关的许多脱氢酶;与红细胞运送氧和二氧化碳功能有关的碳酸酐酶;与骨骼生长发育有关的碱性磷酸酶,等。
造成人体缺锌的因素主要有:一是摄入量不足,谷物和果蔬类食物锌含量低,这是我国人口普遍缺锌的主要原因;二是需求量的增加,如孕妇和哺乳妇对锌的需求量增加,婴幼儿和少年由于生长发育的要求对锌需求量增加,这些人群更容易缺锌;三是体内锌丢失增加,长时间饥饿、烧伤、创伤和大手术病人由于组织破坏分解,可引起尿锌排泄增加;此外,肾病、慢性失血、糖尿病、寄生虫感染及慢性酒精中毒者都会使体内锌丢失。
缺锌对机体的负面影响是多方面的。一是对生长发育和组织再生的影响,锌广泛参与核酸和蛋白质的代谢,缺锌后人体中锌依赖酶的活性降低,妨碍细胞的正常复制和分化,研究证实发育期儿童缺锌的早期表现是生长迟缓或停滞,缺锌可妨碍正常的软骨生成和钙化过程,影响儿童生长发育。缺锌者胶元蛋白合成不足,伤口愈合不好,易发生感染。二是对性器官和性功能的影响。锌缺乏可引起男性第二性征及女性生殖器发育迟缓,青年男女均有性腺机能减退现象,性功能低下。三是锌和激素之间的相互作用,锌不但参与胰岛素合成,并有稳定胰岛素结构的作用,缺锌可使胰岛素降解加剧,引起血中胰岛素水平下降及对葡萄糖利用串减少,葡萄糖耐量下降,且多数随尿病患者伴有锌吸收不良。缺锌还导致体内胸腺素的产量和活性及T细胞的功能降低,机体免疫能力减退。四是缺锌可引起血液内视黄醇结合蛋白的浓度降低,影响组织对维生素A的利用,使人的视力和暗适应能力下降。
最早使用的补锌药物是硫酸锌,但是由于对胃肠粘膜有刺激性而引起恶心、呕吐等副作用,目前已较少使用。因此,近年来人们尝试使用有机锌制剂,包括醋酸锌、枸橼酸锌、乳清酸-精氨酸锌、甘草酸锌、葡萄糖酸锌、L-天门冬氨酸螯合锌、L-赖氨酸螯合锌、甘氨酸锌、L-苏糖酸锌、果糖二磷酸锌、乙酰谷酰胺锌,等。有机锌的制备复杂,价格不菲,且绝大多数效果尚不能肯定。
发明内容
本发明的目的是提供一种以水滑石为载体的口服补锌剂及其制备与使用方法。
本发明的补钒剂是一种含锌酸根离子的水滑石,按重量百分比计,锌在水滑石中的含量为9~11%。
所说的水滑石是一种层状化合物,由Mg、Al的氢氧化物组成基本结构层,层间充填了锌酸根阴离子和水分子,其代表性化学结构如下:
[Mg4-xAlx(OH)7+x]2ZnO2·4H2OX=1~2。
一种以水滑石为载体的口服补锌剂的制备方法包括以下步骤:
1)将铝盐溶于水中配制成浓度为0.5~5M的溶液,向溶液中加入克分子数1~3倍于铝盐的镁盐,搅拌直至全溶,制得溶液A;
2)将克分子数等于铝盐和镁盐克分子数总量四分之一的Na2ZnO2溶于水中,配成浓度为0.5~5M的溶液,再向溶液中加入克分子数为铝盐克分子数三倍和镁盐克分子数两倍的NaOH,搅拌直至全溶,制得溶液B;
3)将上述A、B两种溶液加热至80~90℃,搅拌混合,得到悬浮液;
4)将悬浮液放入水浴锅中,在80~90℃温度下晶化12~24小时;
5)将步骤4)所得产物过滤、抽滤或离心脱水、用80~90℃的热水洗2~3次。放入烘箱中,在60~80℃下烘干,研磨至小于200目;
6)将步骤5)所得粉体压制成每片重量为0.05~0.1克的片剂,即为口服补锌剂。
所说的铝盐为氯化铝、硝酸铝、硫酸铝及其水合物,所说的镁盐为氯化镁、硝酸镁、硫酸镁及其水合物。
另一种以水滑石为载体的口服补锌剂的制备方法包括以下步骤:
1)将铝碳酸镁在450~550℃温度下加热,制得铝镁双金属氧化物;
2)将铝镁双金属氧化物研磨至小于200目,加水搅拌均匀,制成浓度为5~25%的悬浮浆液;
3)将重量等于铝碳酸镁20~22%的锌酸钠配置成5~15%的溶液,并加入重量相当于锌酸钠5~20%的NaOH,搅拌使其完全溶解;
4)将悬浮浆液以及锌酸钠和NaOH的混和溶液加热至80~90℃,搅拌混合,将混合物放入水浴锅中,在80~90℃温度下晶化12~24小时;
5)将步骤4)所得产物过滤、抽滤或离心脱水、用80~90℃的热水洗2~3次。放入烘箱中,在60~80℃下烘干,研磨至小于200目;
6)将步骤5)所得粉体压制成每片重量为0.05~0.1克的片剂,即为口服补锌剂。
所说的市售铝碳酸镁是一种层状化合物,由Mg、Al的氢氧化物组成基本结构层,层间充填了碳酸根阴离子和水分子,其代表性化学结构如下:
[Mg4-xAlx(OH)7+x]2CO3·4H2OX=1~2。
本发明的以水滑石为载体的口服补锌剂的使用方法,是用于人类口服,儿童每天0.05~0.1克,成人每天0.1~0.15克,孕妇与老年人每天0.15~0.20克,分2~3次于饭前半小时服用。
本发明的优点是:
1)所用原料均为常见混合物,成本低廉,生产工艺流程简单,设备投资省;
2)水滑石的缓释效应及其与胃酸反应产物提高了锌酸盐的使用安全性,减轻了直接服用锌酸盐、锌盐纯品带来的腹泻、肠胃不适等副作用;
3)载体水滑石与胃肠道粘膜的亲和性高,大大提高了锌的吸收率,同时也降低了环境残留量;
4)使用方便,适用范围广泛。
具体实施方式
水滑石又称为双金属氢氧化物,是一种由两种不同价态的金属氧化物组成的人工合成物,简称LDH(Layered Double hydroxides)。它具有类似于水镁石(Mg(OH)2)的层状结构,其前身为水滑石类化合物,亦被称为阴离子粘土。水滑石的化学结构通式为:
[Mg4-xAlx(OH)7+x]2ZnO2·4H2O其中X=1~2。以上结构式可以看作是水镁石中的Mg2+离子被Al3+部分替代的产物,为平衡结构层的正电荷,在结构层之间又充填了锌酸根阴离子,此外还有水分子。以水滑石作为锌元素的载体,是因为它是一种碱性化合物,口服后能与胃酸反应,缓慢释放出锌离子,并形成胶态物质,对胃粘膜起保护作用。水滑石的缓释作用降低了锌离子的瞬间浓度,而胶态物质的形成有效缓解了对胃的刺激,从而降低了锌离子可能引起的副作用。
本发明采用共沉淀法制得锌酸根型水滑石,主要原料是镁盐、铝盐、锌酸钠和烧碱。其中,镁盐和铝盐可采用硫酸盐、硝酸盐和盐酸盐及其水合物。镁盐与铝盐的克分子比例一般应控制在1∶1至3∶1范围。在配制溶液A时,镁盐与铝盐的溶解顺序并不重要。溶液B由锌酸钠与烧碱配制而成,其中锌酸钠克分子数等于铝盐和镁盐克分子数总量的四分之一,烧碱的克分子数是为铝盐克分子数三倍和镁盐克分子数两倍之和,二者的溶解顺序并不重要。注意,加入烧碱是为了使溶液中的Mg2+和Al3+形成氢氧化物沉淀,实际操作时烧碱的用量应过量5~10%,以保证溶液中锌酸根的稳定。
将溶液A和溶液B混和前分别加热,是为了消除溶解CO2对溶液中锌酸根离子的竞争性吸附,基于同样的原因,晶化过程应在接近于沸点的温度下进行,水洗也应使用近于沸点的热水。
市售铝碳酸镁是铝镁碳酸根型水滑石的别名,在医药行业它的商品名称又叫“威地美”,具有中和胃酸、胆酸,保护胃粘膜的功效。以铝碳酸镁为原料合成能使工艺流程简化,基本方法是通过加热使铝碳酸镁分解成铝镁双金属氧化物:
铝镁双金属氧化物与溶液中的锌酸根离子和水分子反应,生成锌酸根型水滑石:
加入到锌酸钠溶液中的烧碱未参与反应,目的是保持锌酸根离子的稳定。
将锌元素搭载到水滑石上的反应属于化学吸附反应。其原理是,水滑石在水溶液中具有获取阴离子与水分子的强烈倾向,以恢复重建水滑石的结构。在混和前将两种反应物分别加热,是为了消除溶解CO2对溶液中锌酸根离子的竞争性吸附,基于同样的原因,晶化过程应在接近于沸点的温度下进行,水洗也应使用近于沸点的热水。
供口服的锌酸根型水滑石需压制成每片重量为0.05~0.1克的片剂,主要是为服用方便及掌握剂量。片剂中的锌含量为片剂自身重量的9~11%,平均10%。这种口服补锌剂的使用方法是,儿童每天0.05~0.1克,成人每天0.1~0.15克,孕妇与老年人每天0.15~0.20克,分2~3次于饭前半小时服用。
下面结合实施例进一步说明本发明。
实施例1:共沉淀法制备水滑石,步骤如下:
1)将0.225mol Mg(NO3)2和0.075mol Al(NO3)2溶于300mL水中配成溶液A;
2)将0.075mol Na2ZnO2和0.74mol NaOH溶于300mL水中配成溶液B;
3)将上述A、B两种溶液加热至90℃,在强烈搅拌的同时将两溶液快速混合,得到白色悬浮液;
4)将悬浮液放入水浴锅中,在90℃温度下晶化12小时;
5)将步骤4)所得产物离心脱水,用接近沸点的热水清洗2~3次。放入烘箱中,在60℃下烘干,研磨至小于200目;
6)将步骤5)所得粉体压制成每片重量为0.05克的片剂,即为口服补锌剂。
实施例2:共沉淀法制备水滑石,步骤如下:
1)将0.2mol Mg(NO3)2和0.2mol Al(NO3)2溶于250mL水中配成溶液A;
2)将0.1mol Na2ZnO2和1.1mol NaOH溶于250mL水中配成溶液B;
3)将上述A、B两种溶液加热至80℃,在强烈搅拌的同时将两溶液快速混合,得到白色悬浮液;
4)将悬浮液放入水浴锅中,在80℃温度下晶化24小时;
5)将步骤4)所得产物离心脱水,用接近沸点的热水清洗3次。放入烘箱中,在80℃下烘干,研磨至小于200目;
6)将步骤5)所得粉体压制成每片重量为0.1克的片剂,即为口服补锌剂。
实施例3:采用市售铝碳酸镁为原料按以下步骤制备而成:
1)称取100克铝碳酸镁在550℃温度下加热,制得铝镁双金属氧化物;
2)将铝镁双金属氧化物研磨至小于200目,加500毫升水搅拌均匀,制成悬浮浆液;
3)称取22克锌酸钠,溶入200毫升水中,再加入1.5克NaOH,搅拌使其完全溶解;
4)将悬浮浆液以及锌酸钠和NaOH的混和溶液加热至90℃,在强烈搅拌的同时将二者快速混合,将混合物放入水浴锅中,在90℃温度下晶化12小时;
5)将步骤4)所得产物离心脱水、用接近沸点的热水洗3次。放入烘箱中,在80℃下烘干,研磨至小于200目;
6)将步骤5)所得粉体压制成每片重量为0.1克的片剂,即为口服补锌剂。
实施例4:采用市售铝碳酸镁为原料按以下步骤制备而成:
1)称取100克铝碳酸镁在450℃温度下加热,制得铝镁双金属氧化物;
2)将铝镁双金属氧化物研磨至小于200目,加300毫升水搅拌均匀,制成悬浮浆液;
3)称取20克锌酸钠,溶入200毫升水中,再加入3克NaOH,搅拌使其完全溶解;
4)将悬浮浆液以及锌酸钠和NaOH的混和溶液加热至80℃,在强烈搅拌的同时将二者快速混合,将混合物放入水浴锅中,在80℃温度下晶化24小时;
5)将步骤4)所得产物离心脱水、用接近沸点的热水洗2次。放入烘箱中,在60℃下烘干,研磨至小于200目;
6)将步骤5)所得粉体压制成每片重量为0.05克的片剂,即为口服补锌剂。
本发明提供了一种以水滑石为载体的口服补锌剂及其制备与使用方法。该发明涉及的原料来源广泛,制备方法与工艺流程简单,生产成本较低,易于推广实施。基于本发明所制得的口服补锌剂,能通过缓释作用为人或动物提供必需的微量元素锌,减轻了直接服用无机锌盐、锌酸盐带来的各种副作用,增加了锌的吸收率。所补充的锌元素能够预防和治疗因锌缺乏引起的各种疾病。
Claims (7)
1.一种以水滑石为载体的口服补锌剂,其特征是,它是一种含锌酸根离子的水滑石,按重量百分比计,锌在水滑石中的含量为9~11%。
2.根据权利要求1所述的一种以水滑石为载体的口服补锌剂,其特征在于所说的水滑石是一种层状化合物,由Mg、Al的氢氧化物组成基本结构层,层间充填了锌酸根阴离子和水分子,其代表性化学结构如下:
[Mg4-XAlX(OH)7+X]2ZnO2·4H2OX=1~2。
3.一种以水滑石为载体的口服补锌剂的制备方法,其特征在于它包括以下步骤:
1)将铝盐溶于水中配制成浓度为0.5~5M的溶液,向溶液中加入克分子数1~3倍于铝盐的镁盐,搅拌直至全溶,制得溶液A;
2)将克分子数等于铝盐和镁盐克分子数总量四分之一的Na2ZnO2溶于水中,配成浓度为0.5~5M的溶液,再向溶液中加入克分子数为铝盐克分子数三倍和镁盐克分子数两倍的NaOH,搅拌直至全溶,制得溶液B;
3)将上述A、B两种溶液加热至80~90℃,搅拌混合,得到悬浮液;
4)将悬浮液放入水浴锅中,在80~90℃温度下晶化12~24小时;
5)将步骤4)所得产物过滤、抽滤或离心脱水、用80~90℃的热水洗2~3次。放入烘箱中,在60~80℃下烘干,研磨至小于200目;
6)将步骤5)所得粉体压制成每片重量为0.05~0.1克的片剂,即为口服补锌剂。
4.根据权利要求3所述的一种以水滑石为载体的口服补锌剂的制备方法,其特征是所说的铝盐为氯化铝、硝酸铝、硫酸铝及其水合物,所说的镁盐为氯化镁、硝酸镁、硫酸镁及其水合物;
5.一种以水滑石为载体的口服补锌剂的制备方法,其特征在于它包括以下步骤:
1)将铝碳酸镁在450~550℃温度下加热,制得铝镁双金属氧化物;
2)将铝镁双金属氧化物研磨至小于200目,加水搅拌均匀,制成浓度为5~25%的悬浮浆液;
3)将重量等于铝碳酸镁20~22%的锌酸钠配置成5~15%的溶液,并加入重量相当于锌酸钠5~20%的NaOH,搅拌使其完全溶解;
4)将悬浮浆液以及锌酸钠和NaOH的混和溶液加热至80~90℃,搅拌混合,将混合物放入水浴锅中,在80~90℃温度下晶化12~24小时;
5)将步骤4)所得产物过滤、抽滤或离心脱水、用80~90℃的热水洗2~3次。放入烘箱中,在60~80℃下烘干,研磨至小于200目;
6)将步骤5)所得粉体压制成每片重量为0.05~0.1克的片剂,即为口服补锌剂。
6.根据权利要求5所述的一种以水滑石为载体的口服补锌剂的制备方法,其特征在于所说的市售铝碳酸镁是一种层状化合物,由Mg、Al的氢氧化物组成基本结构层,层间充填了碳酸根阴离子和水分子,其代表性化学结构如下:
[Mg4-XAlX(OH)7+X]2CO3·4H2OX=1~2。
7.一种以水滑石为载体的口服补锌剂的使用方法,其特征是用于人类口服,儿童每天0.05~0.1克,成人每天0.1~0.15克,孕妇与老年人每天0.15~0.20克,分2~3次于饭前半小时服用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100503567A CN1321646C (zh) | 2005-05-18 | 2005-05-18 | 以水滑石为载体的口服补锌剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100503567A CN1321646C (zh) | 2005-05-18 | 2005-05-18 | 以水滑石为载体的口服补锌剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1698649A true CN1698649A (zh) | 2005-11-23 |
CN1321646C CN1321646C (zh) | 2007-06-20 |
Family
ID=35474999
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100503567A Expired - Fee Related CN1321646C (zh) | 2005-05-18 | 2005-05-18 | 以水滑石为载体的口服补锌剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1321646C (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1911079B (zh) * | 2006-08-24 | 2010-12-01 | 浙江大学 | 负载型超细活性单质砷及制备方法和用途 |
CN116196222A (zh) * | 2023-02-28 | 2023-06-02 | 上海沐良医疗器械有限公司 | 防龋齿添加剂、防龋齿材料、牙科膜片及隐形矫治器 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1076855A (zh) * | 1992-03-30 | 1993-10-06 | 泰山医学院 | 一种天然补锌药的制备方法 |
-
2005
- 2005-05-18 CN CNB2005100503567A patent/CN1321646C/zh not_active Expired - Fee Related
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1911079B (zh) * | 2006-08-24 | 2010-12-01 | 浙江大学 | 负载型超细活性单质砷及制备方法和用途 |
CN116196222A (zh) * | 2023-02-28 | 2023-06-02 | 上海沐良医疗器械有限公司 | 防龋齿添加剂、防龋齿材料、牙科膜片及隐形矫治器 |
Also Published As
Publication number | Publication date |
---|---|
CN1321646C (zh) | 2007-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW201717972A (zh) | 矽酸鋯組合物的延伸用途與其使用方法 | |
CN114432234A (zh) | 一种用于肥胖干预的可凝胶化溶液组合及其使用方法和应用 | |
CN1074762C (zh) | L-苏糖酸铬盐、其制备方法及其应用 | |
CN1698649A (zh) | 以水滑石为载体的口服补锌剂及其制备与使用方法 | |
CN1895282A (zh) | 一种钙补充剂及其制备方法 | |
CN100534998C (zh) | 果糖-1,6-二磷酸-钙盐的制备及其应用 | |
CN109481459B (zh) | 一种复方电解质葡萄糖注射液及其制备方法 | |
CN1517085A (zh) | 多种微量元素注射液与其制备方法及其应用 | |
WO1996038058A1 (fr) | Composition contenant du calcium facilement absorbable et son procede de fabrication | |
CN102552250A (zh) | 畜用复方氨基酸注射液及其制备方法和应用 | |
CN1861091A (zh) | 负载型分子碘的补碘剂及制备方法和用途 | |
CN1857304A (zh) | 控缓释型碘的补碘剂及制备方法和用途 | |
CN101129406A (zh) | 复方阿胶系列产品的配方和制造方法 | |
CN1706499A (zh) | 以坡缕石、蒙脱石为载体的补锌剂及其制备使用方法 | |
CN100486990C (zh) | 一种谷胱甘肽螯合钙及其制备方法,用途和组合物 | |
CN102342400A (zh) | 高钙木糖醇 | |
CN1193769C (zh) | 一种解酒醒酒的保健食品 | |
CN1187091C (zh) | 以双金属氧化物为载体的口服补钒剂及其制备与使用方法 | |
CN1172683C (zh) | 以双金属氧化物为载体的口服补硒剂及其制备与使用方法 | |
RU2400251C1 (ru) | Способ лечения хронической болезни почек в додиализном и диализном периодах и лекарственное средство для его реализации | |
CN1081032C (zh) | 含有糖精锌的药物制剂 | |
CN107595829B (zh) | 一种防治肾性骨营养不良的组合物 | |
CN1301109C (zh) | 钙锌铁口服液及其制备方法 | |
CN1562036A (zh) | 一种营养补充剂 | |
JP2005343862A (ja) | ミネラル含有剤とその用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070620 Termination date: 20100518 |